Abstract

Background

This cohort of “late middle-aged” African Americans has an excess of disability. We aimed to determine associations of circulating cytokine receptors (sTNFR1, sTNFR2, and sIL-6R) and C-reactive protein (CRP) with disability, physical function, and body composition.

Methods

Stratified sampling of two socioeconomically diverse strata of St Louis, Missouri, occurred in 2000–2001. Inclusion criteria were self-reported black or African American race, born 1936–1950 inclusive, and Mini-Mental State Examination score of 16 or greater. In-home evaluations of handgrip strength, lean body mass percentage (LBM%), physical performance, upper and lower body functional limitations (UBFLs and LBFLs), and basic and instrumental activities of daily living (BADLs and IADLs) were collected. Of the 998 participants, 368 had blood sampled at baseline. Serum was stored and assayed in 2006.

Results

Absolute risks were LBFLs of 2 or more, 46%; UBFLs of 1 or more, 23.5%; BADLs of 2 or more, 20.6%; and IADLs of 2 or more, 22.5%. Independent of age, sex, and underlying comorbid conditions, higher CRP and sTNFR were associated with poorer physical performance (β = −1.462, p < .001 and β = −0.618, p = .003), UBFLs (odds ratio [OR] 2.26, 95% confidence interval [CI] 1.1–4.64 and OR 1.39, 95% CI 0.96–2.02), LBFLs (OR 2.30, 95% CI 1.19–4.45 and OR 1.91, 95% CI 1.26–2.91), BADLs (OR 2.79, 95% CI 1.03–5.96 and OR 1.66, 95% CI 1.11–2.46), and IADLs (OR 2.13, 95% CI 1.03–4.41 and OR 1.43, 95% CI 0.99–2.08). Higher CRP (β = −3.251, p <.001), sIL-6R (β = −6.152, p = .013), and lower adiponectin (β = 2.947, p = .052) were associated with lower LBM%.

Conclusions

Higher CRP and sTNFR are independently associated with disability and physical dysfunction. Higher sIL-6R, CRP, and lower adiponectin associate with lower LBM%.

THE African American Health (AAH) project is a study of an urban group of African Americans of “late middle-age.” This cohort has been shown to have dysphoric symptoms and health-related quality of life below that of U.S. national averages (1,2) and an excess of subclinical and frank disability (3). The reason for the poor level of performance in this cohort has not been determined.

Epidemiological evidence has shown an association of cytokines (tumor necrosis factor [TNF] α, interleukin [IL]-6), their soluble receptors, and C-reactive protein (CRP) with lower skeletal muscle mass, strength, and aerobic capacity (4). Evidence also exists, particularly in older people, for an inverse association between self-rated health and circulating cytokines (5). Adiponectin is an anti-inflammatory adipokine that increases insulin sensitivity of skeletal muscle and adipose tissue, increases fatty acid oxidation, and may be protective against diabetes and atherosclerosis (6), two major contributors to the disability burden. Independent of body fatness, African Americans have been shown to have lower adiponectin levels than Caucasians (7). We have shown previously that for women in this cohort, adiponectin is lower in obese women and is associated with increased waist-to-hip ratio, triglyceride levels, and history of stroke (8).

It is therefore plausible to hypothesize that a reduction in skeletal muscle mass mediated by proinflammatory cytokines may contribute to impairments in performance, function, and disability. Such an association has been difficult to show in population and clinical studies, possibly due to the labile nature of circulating proinflammatory cytokines. There is physiological rationale for the measurement of soluble cytokine receptors as plasma concentrations reflect the chronic history of inflammatory immune activation (9). Furthermore, sIL-6Rs prolong the half-life of IL-6 in plasma (10) and enhance the signaling of IL-6 even in tissues lacking membrane-bound IL-6R (11,12). sTNFRs are induced by IL-6 (13) and neutralize the effects of TNFα by preventing the interaction of the cytokine with membrane-bound receptors (14). For this reason, soluble cytokine receptors rather than cytokines themselves were measured as markers of chronic inflammation in this cohort.

It was hypothesized that the poor level of performance of the AAH cohort may be due to a high level of chronic inflammation as indicated by elevated soluble cytokine receptors. This investigation examines the association of soluble cytokine receptors and CRP with body composition, physical performance, functional limitations, and disability.

METHODS

Referent Population and Study Sample

The sampling and data collection procedures of AAH have been previously described in detail (1,3). Briefly, AAH is a population-based longitudinal study of 998 men and women aged 49–65 years at baseline, initiated to examine key issues of disability and frailty among urban-dwelling African Americans. Sampling was designed to recruit approximately equal proportions of participants from two socioeconomically diverse strata. One group was from a poor, inner-city area of St Louis, Missouri, and the other was from suburbs adjacent to the north and west of the city. Inclusion criteria were the following: (a) self-reported black or African American race; (b) birth year from 1936 to 1950, inclusive; and (c) Mini-Mental State Examination score of 16 or greater. Baseline evaluations were done between 2000 and 2001, and the response rate was 76%. The eligible study sample for the current investigation included 368 participants who donated blood at baseline. Of this group, there were 349 participants for whom complete data were available on all laboratory measures, and these participants were included in the current study.

Laboratory Methods

Blood was drawn for laboratory analyses shortly after the baseline, in-home assessment, or at the time of further clinical examinations required for special substudies. Serum was stored until analysis for cytokines in 2006. Adiponectin was determined using a commercially available radioimmunoassay kit (Linco Research, St Charles, MO), with intra-assay and interassay coefficients of variation (CVs) of 5.3% and 8.1%, respectively. CRP was measured with a commercially available High-Sensitivity Enzyme Immunoassay (hsCRP ELISA) kit from MP Biomedicals (Orangeburg, NY). The intra-assay and interassay CVs were 4.5% and 4.1%, respectively. Soluble IL-6R was measured with an ELISA kit from ICN-Biomedicals (Costa Mesa, CA). The intra-assay and interassay CVs were 5.0% and 5.9%, respectively. Soluble TNFR1 and sTNFR2 were measured using ELISA kits (BioSource, Camarillo, CA). Intra-assay and interassay CVs were 4.1% and 7.3% for sTNFR1 and 5.1% and 8.6% for sTNFR2.

Functional Status and Body Composition

Disability was assessed using activities of daily living scales. Basic activities of daily living (BADLs) included seven items (bathing, dressing, eating, transferring bed or chair, walking across a room, getting outside, and using toilet) from the Second Longitudinal Study of Aging (LSOA-II) (15). Instrumental activities of daily living (IADLs) included eight items (preparing meals, shopping for groceries, managing money, making phone calls, doing light housework, doing heavy housework, getting to places outside walking distance, and managing medications) from LSOA-II (15) and Lawton and Brody (16). Lower body functional limitations (LBFLs) included five items (walking a quarter of a mile, walking up and down 10 steps without rest, standing for 2 hours, stooping or kneeling, and lifting 10 pounds), and upper body functional limitations (UBFLs) included three items (reaching overhead, reaching out as if to shake hands, and reaching out to grasp an object). LBFL and UBFL items were from the Nagi’s (17) Physical Performance Scale. BADL, IADL, and LBFL scales were scored as the sum of items on which participants reported difficulty performing a task, and scores on each of these scales were dichotomized as 0–1 difficulty versus 2 or more difficulties. UBFL were scored as the total number of items on which participants reported difficulty performing a task, and scores were dichotomized as no difficulty versus 1 or more difficulties.

Physical performance was measured using the Short Physical Performance Battery (SPPB) (18,19). The SPPB is a summary measure of lower body performance based on three component tasks: standing balance, chairs stands, and usual walking speed. Each component task was scored as 0–4 (range 0 = worst to 4 = best), and a composite score was computed as the sum of scores on component tasks as 0–12 (range 0 = worst to 12 = best). Complete details on the composite SPPB score in AAH are provided by Miller and colleagues (19). Isometric grip strength was assessed using a handgrip dynamometer (Fabrication Enterprises, Inc., Irvington, NY). The mean of three maximal effort trials with the self-reported stronger hand was used in these analyses. The test was performed seated in a chair (without arm rests), with feet flat on the floor and the stronger arm held flat against the side with the elbow at 90°. Lean body mass percentage (LBM%) was assessed using a Tanita 2204 Ultimate Scale (Tanita Corporation of America, Inc., Arlington Heights, IL) and determined as 1 minus percent body fat.

Statistical Analysis

Analyses were performed using SPSS, version 15.0 (SPSS Inc., Chicago, IL). Descriptive statistics are reported as percentages or M ± SD. Values for sIL-6R, sTNFR1, sTNFR2, adiponectin, and CRP were not normally distributed, and due to this, these variables were log transformed for all univariable and multivariable analyses. Chi-square (discrete variables) and independent samples t tests (continuous variables) were used to compare baseline characteristics of the study sample (i.e., AAH participants who donated blood at baseline) versus those not eligible for the study (i.e., AAH participants who did not donate blood or those with missing data on one or more laboratory tests). To examine the independent association of each of the cytokine receptors and CRP with each of the functional and disability outcomes, logistic regression models were computed for discrete outcomes (BADLs, IADLs, LBFL, and UBFL), and ordinary least squares regressions were computed for continuous outcomes (SPPB, maximum handgrip, and LBM%), adjusting for age and sex in each model. To assess the effect of chronic comorbidities on the associations of inflammatory markers with functional and disability outcomes, models were also computed with adjustment for chronic disease status (yes or no), including obesity, hypertension, arthritis, type 2 diabetes, stroke history, asthma, chronic heart disease, congestive heart failure, chronic obstructive pulmonary disease, cancer, and chronic kidney disease.

A factor score (linear combination of variables) was created for the sTNFR1 and sTNFR2 variables due to the high correlation between these variables and to handle multicollinearity in the ordinary least squares regressions. For consistency in the presentation of the results, the sTNFR1/sTNFR2 factor scores were used in all regression models. An alpha level of .05 was accepted as statistically significant.

RESULTS

Table 1 provides sociodemographic, anthropometric, physical performance, functional limitation, and disability indicators of the study sample (N = 349) versus the remaining AAH participants (N = 649). The study sample was slightly older and reported higher BADLs, IADLs, LBFLs, and UBFLs than those not included herein. LBM%; handgrip strength; and serum concentrations of soluble cytokine receptors, CRP, and adiponectin are described in Table 2.

Table 1.

Sociodemographic, Anthropometric, Functional and Disability Characteristics of the Current Study Participants and Other AAH Participants

Variables*Current Study ParticipantsAAH Participants Not in Current Studyp Value
N349649
Age, y56.70 (4.4)56.08 (4.5).037
Gender (% male)33.239.3.059
Geography (% inner city)44.747.3.431
Household income (% <20K p.a.)40.438.4.563
Height (m)1.67 (0.1)1.68 (0.1).052
Weight (kg)86.92 (19.0)86.29 (19.2).636
BMI (kg/m2)31.54 (7.0)30.66 (6.9).071
BADLs (0–7)0.88 (1.6)0.65 (1.4).025
BADLs (% 2 or more)20.614.6.016
IADLs (0–8)0.99 (1.7)0.79 (1.5).053
IADLs (% 2 or more)22.518.4.123
UBFLs (0–3)0.37 (0.7)0.28 (0.6).057
UBFLs (% 1 or more)23.520.7.309
LBFLs (0–5)1.83 (1.8)1.5 (1.8).019
LBFLs (% 2 or more)46.038.3.019
SPPB (0–12)7.93 (3.2)7.99 (3.3).768
Variables*Current Study ParticipantsAAH Participants Not in Current Studyp Value
N349649
Age, y56.70 (4.4)56.08 (4.5).037
Gender (% male)33.239.3.059
Geography (% inner city)44.747.3.431
Household income (% <20K p.a.)40.438.4.563
Height (m)1.67 (0.1)1.68 (0.1).052
Weight (kg)86.92 (19.0)86.29 (19.2).636
BMI (kg/m2)31.54 (7.0)30.66 (6.9).071
BADLs (0–7)0.88 (1.6)0.65 (1.4).025
BADLs (% 2 or more)20.614.6.016
IADLs (0–8)0.99 (1.7)0.79 (1.5).053
IADLs (% 2 or more)22.518.4.123
UBFLs (0–3)0.37 (0.7)0.28 (0.6).057
UBFLs (% 1 or more)23.520.7.309
LBFLs (0–5)1.83 (1.8)1.5 (1.8).019
LBFLs (% 2 or more)46.038.3.019
SPPB (0–12)7.93 (3.2)7.99 (3.3).768

Notes: AAH = African American Health; BADLs = basic activities of daily living; BMI = body mass index; IADLs = instrumental activities of daily living; LBFLs = lower body functional limitations; SPPB = Short Physical Performance Battery; UBFLs = upper body functional limitations.

*

Data presented are MSD), except for dichotomized variables (gender, geography, household income, BADLs, IADLs, UBFLs, and LBFLs), where percentages are reported for a given category.

Table 1.

Sociodemographic, Anthropometric, Functional and Disability Characteristics of the Current Study Participants and Other AAH Participants

Variables*Current Study ParticipantsAAH Participants Not in Current Studyp Value
N349649
Age, y56.70 (4.4)56.08 (4.5).037
Gender (% male)33.239.3.059
Geography (% inner city)44.747.3.431
Household income (% <20K p.a.)40.438.4.563
Height (m)1.67 (0.1)1.68 (0.1).052
Weight (kg)86.92 (19.0)86.29 (19.2).636
BMI (kg/m2)31.54 (7.0)30.66 (6.9).071
BADLs (0–7)0.88 (1.6)0.65 (1.4).025
BADLs (% 2 or more)20.614.6.016
IADLs (0–8)0.99 (1.7)0.79 (1.5).053
IADLs (% 2 or more)22.518.4.123
UBFLs (0–3)0.37 (0.7)0.28 (0.6).057
UBFLs (% 1 or more)23.520.7.309
LBFLs (0–5)1.83 (1.8)1.5 (1.8).019
LBFLs (% 2 or more)46.038.3.019
SPPB (0–12)7.93 (3.2)7.99 (3.3).768
Variables*Current Study ParticipantsAAH Participants Not in Current Studyp Value
N349649
Age, y56.70 (4.4)56.08 (4.5).037
Gender (% male)33.239.3.059
Geography (% inner city)44.747.3.431
Household income (% <20K p.a.)40.438.4.563
Height (m)1.67 (0.1)1.68 (0.1).052
Weight (kg)86.92 (19.0)86.29 (19.2).636
BMI (kg/m2)31.54 (7.0)30.66 (6.9).071
BADLs (0–7)0.88 (1.6)0.65 (1.4).025
BADLs (% 2 or more)20.614.6.016
IADLs (0–8)0.99 (1.7)0.79 (1.5).053
IADLs (% 2 or more)22.518.4.123
UBFLs (0–3)0.37 (0.7)0.28 (0.6).057
UBFLs (% 1 or more)23.520.7.309
LBFLs (0–5)1.83 (1.8)1.5 (1.8).019
LBFLs (% 2 or more)46.038.3.019
SPPB (0–12)7.93 (3.2)7.99 (3.3).768

Notes: AAH = African American Health; BADLs = basic activities of daily living; BMI = body mass index; IADLs = instrumental activities of daily living; LBFLs = lower body functional limitations; SPPB = Short Physical Performance Battery; UBFLs = upper body functional limitations.

*

Data presented are MSD), except for dichotomized variables (gender, geography, household income, BADLs, IADLs, UBFLs, and LBFLs), where percentages are reported for a given category.

Table 2.

LBM%, Handgrip Strength, and Serum Cytokine Concentrations in the Study Sample (N = 349)

Variable*MinimumMaximumMSDN
LBM (%)43.095.062.7410.68306
Handgrip strength (kg)5.0090.036.3914.47325
sIL-6R (ng/mL)1912660.9523.49349
sIL-6R (log10)1.282.101.750.18349
sTNFR1 (ng/mL)1463.334.37349
sTNFR1 (log10)0.041.660.440.21349
sTNFR2 (ng/mL)21328.1410.73349
sTNFR2 (log10)0.182.120.820.22349
sTNFR1 and sTNFR2 factor score (log10)−1.966.160.01.0349
CRP (mg/L)0387.017.20349
CRP (log10)−1.001.580.600.51349
Adiponectin (μg/L)1398.325.57349
Adiponectin (log10)01.590.840.27349
Variable*MinimumMaximumMSDN
LBM (%)43.095.062.7410.68306
Handgrip strength (kg)5.0090.036.3914.47325
sIL-6R (ng/mL)1912660.9523.49349
sIL-6R (log10)1.282.101.750.18349
sTNFR1 (ng/mL)1463.334.37349
sTNFR1 (log10)0.041.660.440.21349
sTNFR2 (ng/mL)21328.1410.73349
sTNFR2 (log10)0.182.120.820.22349
sTNFR1 and sTNFR2 factor score (log10)−1.966.160.01.0349
CRP (mg/L)0387.017.20349
CRP (log10)−1.001.580.600.51349
Adiponectin (μg/L)1398.325.57349
Adiponectin (log10)01.590.840.27349

Notes: CRP = C-reactive protein; LBM% = lean body mass percentage.

*

Both raw and transformed data are presented for each variable, where applicable.

Table 2.

LBM%, Handgrip Strength, and Serum Cytokine Concentrations in the Study Sample (N = 349)

Variable*MinimumMaximumMSDN
LBM (%)43.095.062.7410.68306
Handgrip strength (kg)5.0090.036.3914.47325
sIL-6R (ng/mL)1912660.9523.49349
sIL-6R (log10)1.282.101.750.18349
sTNFR1 (ng/mL)1463.334.37349
sTNFR1 (log10)0.041.660.440.21349
sTNFR2 (ng/mL)21328.1410.73349
sTNFR2 (log10)0.182.120.820.22349
sTNFR1 and sTNFR2 factor score (log10)−1.966.160.01.0349
CRP (mg/L)0387.017.20349
CRP (log10)−1.001.580.600.51349
Adiponectin (μg/L)1398.325.57349
Adiponectin (log10)01.590.840.27349
Variable*MinimumMaximumMSDN
LBM (%)43.095.062.7410.68306
Handgrip strength (kg)5.0090.036.3914.47325
sIL-6R (ng/mL)1912660.9523.49349
sIL-6R (log10)1.282.101.750.18349
sTNFR1 (ng/mL)1463.334.37349
sTNFR1 (log10)0.041.660.440.21349
sTNFR2 (ng/mL)21328.1410.73349
sTNFR2 (log10)0.182.120.820.22349
sTNFR1 and sTNFR2 factor score (log10)−1.966.160.01.0349
CRP (mg/L)0387.017.20349
CRP (log10)−1.001.580.600.51349
Adiponectin (μg/L)1398.325.57349
Adiponectin (log10)01.590.840.27349

Notes: CRP = C-reactive protein; LBM% = lean body mass percentage.

*

Both raw and transformed data are presented for each variable, where applicable.

The age- and sex-adjusted associations of soluble cytokine receptor, CRP, and adiponectin concentrations with LBM%, handgrip strength, SPPB, LBFLs, UBFLs, and disability (BADLs and IADLs) are shown in Table 3. Higher sTNFR factor scores (odds ratio [OR] 1.49, p = .004) and higher CRP levels (OR 1.87, p = .041) were significantly associated with BADL of 2 or more. Higher sTNFR factor scores were significantly associated with IADL of 2 or more (OR 1.60, p = 0.001), LBFL of 2 or more (OR 2.03, p < .001), and UBFL of 1 or more (OR 1.42, p = .008). Both higher sTNFR factor scores (β = −0.768, p < .001) and higher CRP levels (β = −1.296, p < .001) were significantly associated with lower SPPB scores. Higher sIL-6R (β = −8.524, p = .004), higher CRP (β = −5.868, p < .001), and lower adiponectin concentrations (β = 4.655, p = .01) were significantly associated with lower LBM%. The strength of these associations was only slightly modified by substituting either sTNFR1 or sTNFR2 for the sTNFR factor score. In general, sTNFR1 predicted outcomes more strongly than did sTNFR2 (data not shown), and the factor score predicted outcomes with intermediate strength.

Table 3.

Age- and Sex-Adjusted Associations of Cytokines With Disability, Functional Limitations, Physical Performance, Handgrip Strength, and LBM%

Outcomes*
BADLs (2 or more)IADLs (2 or more)LBFLs (2 or more)UBFLs (1 or more)SPPBHandgrip StrengthLBM (%)
sIL-6R (log10)0.84 (0.15–4.75), p = .8450.74 (0.14–3.95), p = .7210.62 (0.14–2.81), p = .5370.59 (0.11–3.10), p = .5320.636 (1.12), p = .571−2.019 (4.47), p = .6528.524 (2.94), p = .004
sTNFR (log10)1.49 (1.13–1.95), p = .0041.60 (1.21–2.11), p = .0012.03 (1.46–2.80), p < .0011.42 (1.10–1.85), p = .0080.768 (0.19), p < .001−1.374 (0.74), p = .0640.144 (0.48), p = .764
CRP (log10)1.87 (1.03–3.40), p = .0411.42 (0.80–2.54), p = .2331.54 (0.92–2.55), p = .0981.62 (0.92–2.87), p = .0941.296 (0.36), p < .0010.429 (1.46); p = .7685.868 (0.94), p < .001
Adiponectin (log10)1.21 (0.41–3.55), p = .7350.68 (0.24–1.93), p = .4720.78 (0.31–1.93), p = .5840.53 (0.19–1.46), p = .2170.004 (0.69), p = .995−2.567 (2.77), p = .3544.655 (1.79), p = .010
Outcomes*
BADLs (2 or more)IADLs (2 or more)LBFLs (2 or more)UBFLs (1 or more)SPPBHandgrip StrengthLBM (%)
sIL-6R (log10)0.84 (0.15–4.75), p = .8450.74 (0.14–3.95), p = .7210.62 (0.14–2.81), p = .5370.59 (0.11–3.10), p = .5320.636 (1.12), p = .571−2.019 (4.47), p = .6528.524 (2.94), p = .004
sTNFR (log10)1.49 (1.13–1.95), p = .0041.60 (1.21–2.11), p = .0012.03 (1.46–2.80), p < .0011.42 (1.10–1.85), p = .0080.768 (0.19), p < .001−1.374 (0.74), p = .0640.144 (0.48), p = .764
CRP (log10)1.87 (1.03–3.40), p = .0411.42 (0.80–2.54), p = .2331.54 (0.92–2.55), p = .0981.62 (0.92–2.87), p = .0941.296 (0.36), p < .0010.429 (1.46); p = .7685.868 (0.94), p < .001
Adiponectin (log10)1.21 (0.41–3.55), p = .7350.68 (0.24–1.93), p = .4720.78 (0.31–1.93), p = .5840.53 (0.19–1.46), p = .2170.004 (0.69), p = .995−2.567 (2.77), p = .3544.655 (1.79), p = .010

Notes: BADLs = basic activities of daily living; CRP = C-reactive protein; IADLs = instrumental activities of daily living; LBFLs = lower body functional limitations; LBM% = lean body mass percentage; SPPB = Short Physical Performance Battery; UBFLs = upper body functional limitations.

*

Results of logistic regressions computed for discrete outcomes (BADLs, IADLs, LBFLs, and UBFLs) are reported as odds ratio (95% confidence intervals). Results of ordinary least squares regressions computed for continuous outcomes (SPPB, handgrip strength, and LBM%) are reported as unstandardized betas (standard errors). Models were adjusted for age and sex.

The sTNFR factor score was used in these analyses. Bold values were used to highlight statistically significant associations.

Table 3.

Age- and Sex-Adjusted Associations of Cytokines With Disability, Functional Limitations, Physical Performance, Handgrip Strength, and LBM%

Outcomes*
BADLs (2 or more)IADLs (2 or more)LBFLs (2 or more)UBFLs (1 or more)SPPBHandgrip StrengthLBM (%)
sIL-6R (log10)0.84 (0.15–4.75), p = .8450.74 (0.14–3.95), p = .7210.62 (0.14–2.81), p = .5370.59 (0.11–3.10), p = .5320.636 (1.12), p = .571−2.019 (4.47), p = .6528.524 (2.94), p = .004
sTNFR (log10)1.49 (1.13–1.95), p = .0041.60 (1.21–2.11), p = .0012.03 (1.46–2.80), p < .0011.42 (1.10–1.85), p = .0080.768 (0.19), p < .001−1.374 (0.74), p = .0640.144 (0.48), p = .764
CRP (log10)1.87 (1.03–3.40), p = .0411.42 (0.80–2.54), p = .2331.54 (0.92–2.55), p = .0981.62 (0.92–2.87), p = .0941.296 (0.36), p < .0010.429 (1.46); p = .7685.868 (0.94), p < .001
Adiponectin (log10)1.21 (0.41–3.55), p = .7350.68 (0.24–1.93), p = .4720.78 (0.31–1.93), p = .5840.53 (0.19–1.46), p = .2170.004 (0.69), p = .995−2.567 (2.77), p = .3544.655 (1.79), p = .010
Outcomes*
BADLs (2 or more)IADLs (2 or more)LBFLs (2 or more)UBFLs (1 or more)SPPBHandgrip StrengthLBM (%)
sIL-6R (log10)0.84 (0.15–4.75), p = .8450.74 (0.14–3.95), p = .7210.62 (0.14–2.81), p = .5370.59 (0.11–3.10), p = .5320.636 (1.12), p = .571−2.019 (4.47), p = .6528.524 (2.94), p = .004
sTNFR (log10)1.49 (1.13–1.95), p = .0041.60 (1.21–2.11), p = .0012.03 (1.46–2.80), p < .0011.42 (1.10–1.85), p = .0080.768 (0.19), p < .001−1.374 (0.74), p = .0640.144 (0.48), p = .764
CRP (log10)1.87 (1.03–3.40), p = .0411.42 (0.80–2.54), p = .2331.54 (0.92–2.55), p = .0981.62 (0.92–2.87), p = .0941.296 (0.36), p < .0010.429 (1.46); p = .7685.868 (0.94), p < .001
Adiponectin (log10)1.21 (0.41–3.55), p = .7350.68 (0.24–1.93), p = .4720.78 (0.31–1.93), p = .5840.53 (0.19–1.46), p = .2170.004 (0.69), p = .995−2.567 (2.77), p = .3544.655 (1.79), p = .010

Notes: BADLs = basic activities of daily living; CRP = C-reactive protein; IADLs = instrumental activities of daily living; LBFLs = lower body functional limitations; LBM% = lean body mass percentage; SPPB = Short Physical Performance Battery; UBFLs = upper body functional limitations.

*

Results of logistic regressions computed for discrete outcomes (BADLs, IADLs, LBFLs, and UBFLs) are reported as odds ratio (95% confidence intervals). Results of ordinary least squares regressions computed for continuous outcomes (SPPB, handgrip strength, and LBM%) are reported as unstandardized betas (standard errors). Models were adjusted for age and sex.

The sTNFR factor score was used in these analyses. Bold values were used to highlight statistically significant associations.

The age-, sex-, and comorbidity-adjusted associations of soluble cytokine receptor, CRP, and adiponectin concentrations with LBM%, handgrip strength, SPPB, LBFLs, UBFLs, and disability (BADL’s and IADLs) are shown in Table 4. Adjustment for comorbidities strengthened the association of CRP with disability, functional limitation, and physical performance outcomes to a level of significance. The associations of sIL-6R, CRP, and adiponectin with LBM% remained, although for adiponectin, the association became marginally significant (p = .051). The associations of the sTNFR factor score with BADLs, UBFLs, and SPPB did not change substantively but became marginally significant for IADLs of 2 or more (p =.060) and UBFLs of 1 or more (p = .082).

Table 4.

Age-, Sex- and Comorbidity-Adjusted Associations of Cytokines With Disability, Functional Limitations, Physical Performance, Handgrip Strength, and LBM%

Outcomes*
BADLs (2 or more)IADLs (2 or more)LBFLs (2 or more)UBFLs (1 or more)SPPBHandgrip StrengthLBM (%)
sIL-6R (log10)0.85 (0.11–6.81), p = .8760.74 (0.10–5.38), p = .7620.51 (0.09–2.93), p = .4460.48 (0.07–3.29), p = .4530.598 (1.01), p = .552−2.058 (4.57), p = .6526.152 (2.47), p = .013
sTNFR (log10)1.66 (1.11–2.46), p = 0.0131.43 (0.99–2.08), p = .0601.91 (1.26–2.91), p = .0021.39 (0.96–2.02), p = .0820.618 (0.21), p = .003−0.964 (0.94), p = .303−0.074 (0.51), p = .886
CRP (log10)2.79 (1.03–5.96), p = .0082.13 (1.03–4.41), p = .0422.30 (1.19–4.45), p = .0132.26 (1.10–4.64), p = .0271.426 (0.35), p < .001−0.269 (1.58), p = .8653.251 (0.84), p < .001
Adiponectin (log10)2.63 (0.72–9.53), p = .1421.03 (0.30–3.54), p = .9591.14 (0.39–3.39), p = .8090.81 (0.25–2.68), p = .732−0.425 (0.62), p = .494−1.530 (2.84), p = .5912.947 (1.51), p = .052
Outcomes*
BADLs (2 or more)IADLs (2 or more)LBFLs (2 or more)UBFLs (1 or more)SPPBHandgrip StrengthLBM (%)
sIL-6R (log10)0.85 (0.11–6.81), p = .8760.74 (0.10–5.38), p = .7620.51 (0.09–2.93), p = .4460.48 (0.07–3.29), p = .4530.598 (1.01), p = .552−2.058 (4.57), p = .6526.152 (2.47), p = .013
sTNFR (log10)1.66 (1.11–2.46), p = 0.0131.43 (0.99–2.08), p = .0601.91 (1.26–2.91), p = .0021.39 (0.96–2.02), p = .0820.618 (0.21), p = .003−0.964 (0.94), p = .303−0.074 (0.51), p = .886
CRP (log10)2.79 (1.03–5.96), p = .0082.13 (1.03–4.41), p = .0422.30 (1.19–4.45), p = .0132.26 (1.10–4.64), p = .0271.426 (0.35), p < .001−0.269 (1.58), p = .8653.251 (0.84), p < .001
Adiponectin (log10)2.63 (0.72–9.53), p = .1421.03 (0.30–3.54), p = .9591.14 (0.39–3.39), p = .8090.81 (0.25–2.68), p = .732−0.425 (0.62), p = .494−1.530 (2.84), p = .5912.947 (1.51), p = .052

Notes: BADLs = basic activities of daily living; CRP = C-reactive protein; IADLs = instrumental activities of daily living; LBFLs = lower body functional limitations; LBM% = lean body mass percentage; SPPB = Short Physical Performance Battery; UBFLs = upper body functional limitations

*

Results of logistic regressions computed for discrete outcomes (BADLs, IADLs, LBFLs, and UBFLs) are reported as odds ratio (95% confidence intervals). Results of ordinary least squares regressions computed for continuous outcomes (SPPB, handgrip strength, and LBM%) are reported as unstandardized betas (standard errors). Models were adjusted for age, sex, obesity, hypertension, arthritis, type 2 diabetes, stroke history, asthma, chronic heart disease, congestive heart failure, chronic obstructive pulmonary disease, cancer, and chronic kidney disease.

The sTNFR factor score was used in these analyses. Bold values were used to highlight statistically significant associations.

Table 4.

Age-, Sex- and Comorbidity-Adjusted Associations of Cytokines With Disability, Functional Limitations, Physical Performance, Handgrip Strength, and LBM%

Outcomes*
BADLs (2 or more)IADLs (2 or more)LBFLs (2 or more)UBFLs (1 or more)SPPBHandgrip StrengthLBM (%)
sIL-6R (log10)0.85 (0.11–6.81), p = .8760.74 (0.10–5.38), p = .7620.51 (0.09–2.93), p = .4460.48 (0.07–3.29), p = .4530.598 (1.01), p = .552−2.058 (4.57), p = .6526.152 (2.47), p = .013
sTNFR (log10)1.66 (1.11–2.46), p = 0.0131.43 (0.99–2.08), p = .0601.91 (1.26–2.91), p = .0021.39 (0.96–2.02), p = .0820.618 (0.21), p = .003−0.964 (0.94), p = .303−0.074 (0.51), p = .886
CRP (log10)2.79 (1.03–5.96), p = .0082.13 (1.03–4.41), p = .0422.30 (1.19–4.45), p = .0132.26 (1.10–4.64), p = .0271.426 (0.35), p < .001−0.269 (1.58), p = .8653.251 (0.84), p < .001
Adiponectin (log10)2.63 (0.72–9.53), p = .1421.03 (0.30–3.54), p = .9591.14 (0.39–3.39), p = .8090.81 (0.25–2.68), p = .732−0.425 (0.62), p = .494−1.530 (2.84), p = .5912.947 (1.51), p = .052
Outcomes*
BADLs (2 or more)IADLs (2 or more)LBFLs (2 or more)UBFLs (1 or more)SPPBHandgrip StrengthLBM (%)
sIL-6R (log10)0.85 (0.11–6.81), p = .8760.74 (0.10–5.38), p = .7620.51 (0.09–2.93), p = .4460.48 (0.07–3.29), p = .4530.598 (1.01), p = .552−2.058 (4.57), p = .6526.152 (2.47), p = .013
sTNFR (log10)1.66 (1.11–2.46), p = 0.0131.43 (0.99–2.08), p = .0601.91 (1.26–2.91), p = .0021.39 (0.96–2.02), p = .0820.618 (0.21), p = .003−0.964 (0.94), p = .303−0.074 (0.51), p = .886
CRP (log10)2.79 (1.03–5.96), p = .0082.13 (1.03–4.41), p = .0422.30 (1.19–4.45), p = .0132.26 (1.10–4.64), p = .0271.426 (0.35), p < .001−0.269 (1.58), p = .8653.251 (0.84), p < .001
Adiponectin (log10)2.63 (0.72–9.53), p = .1421.03 (0.30–3.54), p = .9591.14 (0.39–3.39), p = .8090.81 (0.25–2.68), p = .732−0.425 (0.62), p = .494−1.530 (2.84), p = .5912.947 (1.51), p = .052

Notes: BADLs = basic activities of daily living; CRP = C-reactive protein; IADLs = instrumental activities of daily living; LBFLs = lower body functional limitations; LBM% = lean body mass percentage; SPPB = Short Physical Performance Battery; UBFLs = upper body functional limitations

*

Results of logistic regressions computed for discrete outcomes (BADLs, IADLs, LBFLs, and UBFLs) are reported as odds ratio (95% confidence intervals). Results of ordinary least squares regressions computed for continuous outcomes (SPPB, handgrip strength, and LBM%) are reported as unstandardized betas (standard errors). Models were adjusted for age, sex, obesity, hypertension, arthritis, type 2 diabetes, stroke history, asthma, chronic heart disease, congestive heart failure, chronic obstructive pulmonary disease, cancer, and chronic kidney disease.

The sTNFR factor score was used in these analyses. Bold values were used to highlight statistically significant associations.

DISCUSSION

With the aging of the population, there is increased interest in the factors leading to frailty and disability (20,21). The present study in late middle-aged African American men and women shows strong and independent associations of CRP and higher serum-soluble TNF receptor concentrations with poorer physical performance and higher levels of UBFLs and LBFLs and disability. The etiologies of functional limitations and disability are complex and multifactorial involving processes of physical, cognitive, social, emotional, and behavioral decline. The outcome measures used in the present study reflect different combinations of these factors and thus implicate CRP and sTNFR pathways in physical performances such as balance and walking speed and multifaceted functions from walking across a room, lifting 10 pounds and reaching overhead, to dressing, eating and managing money, and medications.

These associations were independent of underlying chronic comorbidities as indicated by our adjusted models. Kuo and colleagues (22) reported similar independent associations for CRP and disability in men and women aged 60 years and older who participated in National Health and Nutrition Examination Survey between 1999 and 2002 (mean age 70.2 years). CRP was also shown to be associated with disability, independent of health conditions in a population of older adults in the Sacramento Area Latino Study on Aging (23). Leng and colleagues (24) showed an age-, race-, education-, body mass index (BMI)–, and smoking status–independent association of CRP with prevalent frailty in community-dwelling older women but did not adjust for chronic conditions. The present study contributes new and important information in addition to the studies reported earlier. Compared with the NHANES data, the effect sizes for the CRP associations with disability were larger in our cohort (e.g., AAH: BADLs, OR 2.79; IADLs, OR 2.13 and NHANES: BADLs, OR 1.12, IADLs, OR 1.18). These differences could be due to the outcomes analyzed; we compared difficulty in two or more IADLs with one or fewer, whereas NHANES compared difficulty in one or more IADLs with no difficulty, or they could reflect real differences between the populations. Our African American cohort is significantly younger and has higher levels of disability and some chronic diseases than the population studied by Kuo and colleagues. The independent association of sTNFR levels with disability and functional limitations appears to be a novel finding. Beyond the comparisons we present earlier, there are no published data that allow a direct comparison of the effect of cytokines on functional limitations or disability between African American and Caucasian populations.

Elevated TNFα levels have been demonstrated in numerous chronic diseases including cardiovascular disease (25,26), rheumatoid arthritis, and inflammatory bowel disease (27,28), and several TNFα gene polymorphisms have been identified, one of which affects the rate of transcription of the TNFα gene (29,30). The AA genotype of this polymorphism (G-308A) was shown to have a frequency of 3.5% in African Americans compared with 2.4% in white Americans and has been linked to higher CRP levels (31). This may explain partly the comorbidity independent associations of CRP with poorer physical performance, functional limitations, and disability in this cohort. Proinflammatory cytokines, such as TNFα and IL-1, stimulate the production of IL-6, which induces the production and secretion of acute-phase reactants (e.g., CRP) from the liver (32). Increased CRP levels have been associated with an increased risk of stroke, peripheral artery disease, myocardial infarction, type 2 diabetes mellitus, and metabolic syndrome (33–38). The AAH cohort has a high prevalence of chronic disease and risk factors associated with increased levels of proinflammatory cytokines. The prevalence of risk factors and chronic diseases in the study sample were as follows: overweight (BMI ≥25) 82%, obesity (BMI ≥30) 49%, hypertension 67%, arthritis 50%, type 2 diabetes mellitus 26%, stroke 10%, asthma 11%, chronic heart disease 9%, congestive heart failure 4%, chronic obstructive pulmonary disease 8%, cancer 8%, and chronic kidney disease 5%. The results of the present analysis suggest effects of CRP and sTNFR on functional limitations and disability independent of these factors.

Studies of clinical samples have shown associations of cytokines with physical performance, muscle strength, and body composition. Toth and colleagues (4) showed that chronic heart failure patients had increased IL-6, sTNFR2, sIL-6R, and CRP levels when compared with healthy controls; these levels were inversely associated with aerobic capacity. Higher TNFα levels were correlated with lower skeletal muscle mass, and higher TNFα and IL-6 levels were associated with reduced leg and forearm muscle strength (4). The same group also reported an increase in circulating sTNFR2 and reduced insulin-like growth factor-1 levels in old (72 ± 1 years) versus young (29 ± 2 years) volunteers of mixed gender and showed that sTNFR2, CRP, and IL-6 concentrations were inversely associated with myosin heavy chain (MyHC) protein synthesis rate (39). Intriguingly, in the present study, a less favorable body composition, as indicated by lower LBM% (increased fat mass%), was associated with a serum adipocytokine profile of higher sIL-6R and CRP and lower adiponectin levels but not with sTNFR. Moreover, there was no association of any cytokine with handgrip strength. On the basis of this finding, we speculate that much of the association of CRP and sTNFR with functional limitations and disabilities in this population may be due less to effects on crude muscle strength and more to negative effects on cognitive processes required for some functional tasks.

Mechanistically, however, there is strong evidence of cytokine pathway involvement in skeletal muscle atrophy. IL-6, TNFα, and IL-1β have been identified as contributors to myofiber degradation and skeletal muscle atrophy (40). The TNF and IL signaling pathways can regulate DNA fragmentation, apoptosis, and atrophy in skeletal muscle via phosphorylation of I Kappa B kinase and activation of nuclear factor kappa (NFκB) (41,42). In skeletal muscle, activation of NFκB induces translocation to the nucleus where it binds to DNA and increases the transcription of the ubiquitin E3 ligases Atrogin-1 (aka MAFbx) and muscle ring-finger protein-I (43,44). These events also inhibit myogenic differentiation by both suppressing the transcription and promoting the degradation of myosin D (45,46) and also inhibit the transcription of MyHC (47).

It is not possible to elucidate temporal effects of cytokine activation, changes in body composition, muscle strength and physical performance, incident functional limitations and disability, given the cross-sectional nature of this study. Although an effect of CRP is common, the otherwise differential cytokine profiles associated with LBM% compared with physical performance, functional limitations, and disability suggest that changes in body composition may be driven by different factors than functional changes and disability; it is possible that one may precede and predict the other (Figure 1). Such associations may be driven by an epigenetic interaction of psychosocial and environmental factors with high frequencies of (adipo) cytokine gene polymorphisms in the African American population. Well-designed longitudinal analyses are required to examine these hypotheses. It is also possible that measurement of IL-6 rather than the soluble receptor could have resulted in different associations with body composition, functional limitations, and disability.

Figure 1.

The proposed associations between changes in body composition, cytokines, and progression along the disability continuum. This figure represents the associations between changes in body composition, circulating cytokines, and progression along the disability continuum. This basic model requires longitudinal interrogation using valid and reliable measurement of circulating cytokines (soluble receptors), body fat (including visceral adiposity), and direct measurements of physical (and cognitive) function and disability.

Some selection bias may have occurred in this subsample of the AAH study cohort as participants with full data available for this analysis were older and had higher BADLs and LBFLs when compared with the rest of the cohort. Nevertheless, an underrepresentation of younger, less functionally limited, and less disabled people would tend to reduce the ability for this analysis to detect significant associations with these outcomes.

It is concluded that higher CRP and sTNFR are associated with disability and physical dysfunction, independent of underlying chronic conditions, age, and sex. Higher sIL-6R, CRP, and lower adiponectin associate with lower LBM%. Temporal associations between body composition changes, cytokines, and progression along the disability continuum require longitudinal study.

FUNDING

This study was supported by a grant from National Institute of Health to D.K.M (R01 AG10436).

CONFLICTOF INTEREST

M.T.H., PhD, was at Saint Louis University during the initial stages of this work and is currently an National Health and Medical Research Council Training (postdoctoral) Fellow (Public Health) at the SANSOM Institute, and Division of Health Sciences, University of South Australia and Spencer Gulf Rural Health School, University of South Australia and The University of Adelaide. M.T.H. contributed to the analysis and interpretation of data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content and data analysis. T.K.M., PhD, contributed to conception and design of the study, acquisition of data, performed the data analysis and contributed to interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content, and provided administrative and technical support. D.K.M., MD, was involved in the conception and design of the study; acquisition of data; drafting of the manuscript; and critical revision of the manuscript for important intellectual content and for obtaining funding and administrative, technical, and material support. P.P., MSc, contributed to acquisition of data, drafting of the manuscript and technical and material support, and performing the laboratory analysis of serum specimens. H.M.P. III, MD, contributed to the concept and design of the study and critical revision of the manuscript for important intellectual content and material support for laboratory assays. M.M.H., PhD, contributed to acquisition of data, drafting of the manuscript, and technical support. W.A.B., MD, contributed to the conception and design of the study; acquisition of data; analysis and interpretation of data; drafting of the manuscript; and critical revision of the manuscript for important intellectual content, statistical analysis, administrative, technical, and material support, and supervision. J.E.M., MB Bch, was involved in the conception and design of the study and critical revision of the manuscript for important intellectual content, administrative, technical, and material support, and supervision. T.K.M. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. There are no conflicts of interest to declare for any of the authors. The funding agency had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript.

References

1.
Miller
DK
Malmstrom
TK
Joshi
S
Andresen
EM
Morley
JE
Wolinsky
FD
Clinically relevant levels of depressive symptoms in community-dwelling middle-aged African Americans
J Am Geriatr Soc
2004
, vol. 
52
 
5
(pg. 
741
-
748
)
2.
Wolinsky
FD
Miller
DK
Andresen
EM
Malmstrom
TK
Miller
JP
Health-related quality of life in middle-aged African Americans
J Gerontol B Psychol Sci Soc Sci
2004
, vol. 
59
 
2
(pg. 
S118
-
S123
)
3.
Miller
DK
Wolinsky
FD
Malmstrom
TK
Andresen
EM
Miller
JP
Inner city, middle-aged African Americans have excess frank and subclinical disability
J Gerontol A Biol Sci Med Sci
2005
, vol. 
60
 
2
(pg. 
207
-
212
)
4.
Toth
MJ
Ades
PA
Tischler
MD
Tracy
RP
LeWinter
MM
Immune activation is associated with reduced skeletal muscle mass and physical function in chronic heart failure
Int J Cardiol
2006
, vol. 
109
 
2
(pg. 
179
-
187
)
5.
Unden
AL
Andreasson
A
Elofsson
S
, et al. 
Inflammatory cytokines, behaviour and age as determinants of self-rated health in women
Clin Sci (Lond)
2007
, vol. 
112
 
6
(pg. 
363
-
373
)
6.
Duncan
BB
Schmidt
MI
Pankow
JS
, et al. 
Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study
Diabetes
2004
, vol. 
53
 
9
(pg. 
2473
-
2478
)
7.
Ferris
WF
Naran
NH
Crowther
NJ
Rheeder
P
van der Merwe
L
Chetty
N
The relationship between insulin sensitivity and serum adiponectin levels in three population groups
Horm Metab Res
2005
, vol. 
37
 
11
(pg. 
695
-
701
)
8.
Rolland
YM
Haren
MT
Patrick
P
, et al. 
Adiponectin levels in obese and non-obese middle-aged African–American women
Obes Res Clin Pract
2007
, vol. 
1
 
1
(pg. 
27
-
37
)
9.
Dibbs
Z
Thornby
J
White
BG
Mann
DL
Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials
J Am Coll Cardiol
1999
, vol. 
33
 
7
(pg. 
1935
-
1942
)
10.
Peters
M
Jacobs
S
Ehlers
M
, et al. 
The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6
J Exp Med
1996
, vol. 
183
 
4
(pg. 
1399
-
1406
)
11.
Dziedzic
T
Gryz
EA
Turaj
W
Slowik
A
Szczudlik
A
Serum interleukin-6 soluble receptor in relation to interleukin-6 in stroke patients
J Mol Neurosci
2004
, vol. 
24
 
2
(pg. 
293
-
298
)
12.
Novick
D
Shulman
LM
Chen
L
Revel
M
Enhancement of interleukin 6 cytostatic effect on human breast carcinoma cells by soluble IL-6 receptor from urine and reversion by monoclonal antibody
Cytokine
1992
, vol. 
4
 
1
(pg. 
6
-
11
)
13.
Tilg
H
Trehu
E
Atkins
MB
Dinarello
CA
Mier
JW
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55
Blood
1994
, vol. 
83
 
1
(pg. 
113
-
118
)
14.
Mohler
KM
Torrance
DS
Smith
CA
, et al. 
Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists
J Immunol
1993
, vol. 
151
 
3
(pg. 
1548
-
1561
)
15.
Data File Documentation, National Health Interview Second Supplement on Aging (machine readable data file and documentation)
1994
 
In: Statistics NCfH, ed. Hyattsville, MD: National Center for Health Statistics
16.
Lawton
MP
Brody
EM
Assessment of older people: self-maintaining and instrumental activities of daily living
Gerontologist
1969
, vol. 
9
 
3
(pg. 
179
-
186
)
17.
Nagi
SZ
An epidemiology of disability among adults in the United States
Milbank Mem Fund Q Health Soc
1976
, vol. 
54
 
4
(pg. 
439
-
467
)
18.
Guralnik
JM
Simonsick
EM
Ferrucci
L
, et al. 
A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission
J Gerontol
1994
, vol. 
49
 
2
(pg. 
M85
-
M94
)
19.
Miller
D
Wolinsky
F
Andresen
E
Adverse outcomes and correlates of change in the short physical performance battery over 36 months in the African American Health project
J Gerontol A Biol Sci Med Sci
2008
, vol. 
63
 
5
(pg. 
487
-
494
)
20.
Ling
SM
Simonsick
EM
Ferrucci
L
A painful interface between normal aging and disease
J Gerontol A Biol Sci Med Sci
2007
, vol. 
62
 
6
(pg. 
613
-
615
)
21.
Morley
JE
Perry
HM
III
Miller
DK
Editorial: something about frailty
J Gerontol A Biol Sci Med Sci
2002
, vol. 
57
 
11
(pg. 
M698
-
M704
)
22.
Kuo
HK
Bean
JF
Yen
CJ
Leveille
SG
Linking C-reactive protein to late-life disability in the National Health and Nutrition Examination Survey (NHANES) 1999–2002
J Gerontol A Biol Sci Med Sci
2006
, vol. 
61
 
4
(pg. 
380
-
387
)
23.
Aiello
AE
Haan
MN
Pierce
CM
Simanek
AM
Liang
J
Persistent infection, inflammation, and functional impairment in older Latinos
J Gerontol A Biol Sci Med Sci
2008
, vol. 
63
 
6
(pg. 
610
-
618
)
24.
Leng
SX
Xue
QL
Tian
J
Walston
JD
Fried
LP
Inflammation and frailty in older women
J Am Geriatr Soc
2007
, vol. 
55
 
6
(pg. 
864
-
871
)
25.
Skoog
T
Dichtl
W
Boquist
S
, et al. 
Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men
Eur Heart J
2002
, vol. 
23
 
5
(pg. 
376
-
383
)
26.
Ridker
PM
Rifai
N
Pfeffer
M
Sacks
F
Lepage
S
Braunwald
E
Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction
Circulation
2000
, vol. 
101
 
18
(pg. 
2149
-
2153
)
27.
Baugh
JA
Bucala
R
Mechanisms for modulating TNF alpha in immune and inflammatory disease
Curr Opin Drug Discov Devel
2001
, vol. 
4
 
5
(pg. 
635
-
650
)
28.
Furst
DE
Breedveld
FC
Kalden
JR
, et al. 
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003)
Ann Rheum Dis
2003
, vol. 
62
 
suppl 2
(pg. 
ii2
-
ii9
)
29.
Kroeger
KM
Carville
KS
Abraham
LJ
The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription
Mol Immunol
1997
, vol. 
34
 
5
(pg. 
391
-
399
)
30.
Wilson
AG
Symons
JA
McDowell
TL
McDevitt
HO
Duff
GW
Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation
Proc Natl Acad Sci U S A
1997
, vol. 
94
 
7
(pg. 
3195
-
3199
)
31.
Lakka
HM
Lakka
TA
Rankinen
T
, et al. 
The TNF-alpha G-308A polymorphism is associated with C-reactive protein levels: the HERITAGE Family Study
Vascul Pharmacol
2006
, vol. 
44
 
5
(pg. 
377
-
383
)
32.
Libby
P
Ridker
PM
Maseri
A
Inflammation and atherosclerosis
Circulation
2002
, vol. 
105
 
9
(pg. 
1135
-
1143
)
33.
McDermott
MM
Guralnik
JM
Corsi
A
, et al. 
Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study
Am Heart J
2005
, vol. 
150
 
2
(pg. 
276
-
281
)
34.
Hu
FB
Meigs
JB
Li
TY
Rifai
N
Manson
JE
Inflammatory markers and risk of developing type 2 diabetes in women
Diabetes
2004
, vol. 
53
 
3
(pg. 
693
-
700
)
35.
Lip
GY
Patel
JV
Hughes
E
Hart
RG
High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation. Relationship to stroke risk factors, stroke risk stratification schema, and prognosis
Stroke
2007
, vol. 
38
 
4
(pg. 
1229
-
1237
)
36.
Schlager
O
Exner
M
Mlekusch
W
, et al. 
C-reactive protein predicts future cardiovascular events in patients with carotid stenosis
Stroke
2007
, vol. 
38
 
4
(pg. 
1263
-
1268
)
37.
Ishikawa
S
Kayaba
K
Gotoh
T
Nakamura
Y
Kajii
E
Metabolic syndrome and C-reactive protein in the general population: JMS Cohort Study
Circ J
2007
, vol. 
71
 
1
(pg. 
26
-
31
)
38.
Yang
SP
Gong
CX
Cao
BY
Yan
C
Relationship between serum high-sensitivity C-reactive protein and obesity and impaired glycose metabolism in children and adolescents
Zhonghua Er Ke Za Zhi
2006
, vol. 
44
 
12
(pg. 
933
-
936
)
39.
Toth
MJ
Matthews
DE
Tracy
RP
Previs
MJ
Age-related differences in skeletal muscle protein synthesis: relation to markers of immune activation
Am J Physiol Endocrinol Metab
2005
, vol. 
288
 
5
(pg. 
E883
-
E891
)
40.
Thissen
JP
How proinflammatory cytokines may impair growth and cause muscle wasting
Horm Res
2007
, vol. 
67
 
suppl 1
(pg. 
64
-
70
)
41.
Phillips
T
Leeuwenburgh
C
Muscle fiber specific apoptosis and TNF-alpha signaling in sarcopenia are attenuated by life-long calorie restriction
FASEB J
2005
, vol. 
19
 
6
(pg. 
668
-
670
)
42.
Chevrel
G
Granet
C
Miossec
P
Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors
Ann Rheum Dis
2005
, vol. 
64
 
9
(pg. 
1257
-
1262
)
43.
Tisdale
MJ
The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting
J Support Oncol
2005
, vol. 
3
 
3
(pg. 
209
-
217
)
44.
Spate
U
Schulze
PC
Proinflammatory cytokines and skeletal muscle
Curr Opin Clin Nutr Metab Care
2004
, vol. 
7
 
3
(pg. 
265
-
269
)
45.
Langen
RC
Van Der Velden
JL
Schols
AM
Kelders
MC
Wouters
EF
Janssen-Heininger
YM
Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization
FASEB J
2004
, vol. 
18
 
2
(pg. 
227
-
237
)
46.
Guttridge
DC
Mayo
MW
Madrid
LV
Wang
CY
Baldwin
AS
Jr
NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia
Science
2000
, vol. 
289
 
5488
(pg. 
2363
-
2366
)
47.
Li
YP
Reid
MB
NF-kappaB mediates the protein loss induced by TNF-alpha in differentiated skeletal muscle myotubes
Am J Physiol Regul Integr Comp Physiol
2000
, vol. 
279
 
4
(pg. 
R1165
-
R1170
)

Author notes

Decision Editor: Luigi Ferrucci, MD, PhD